hypoimmune-modified cells

Hypoimmune-modified cells are genetically engineered human cells designed to evade detection and destruction by the host immune system after transplantation. This is achieved by disrupting the expression of key immune recognition molecules such as **B2M** (encoding β2-microglobulin, which is essential for MHC class I expression) and **CIITA** (a master regulator for MHC class II expression) to eliminate MHC class I and II surface proteins. Additionally, these cells often overexpress anti-apoptotic proteins or immunomodulatory surface proteins such as **CD47** (“don’t eat me” signal) to further diminish immune rejection. These modifications make the cells effectively “invisible” to T cells, NK cells, and antigen-presenting cells, potentially enabling universal, off-the-shelf cell therapies without the need for immunosuppression. Developed cell types include induced pluripotent stem cells (iPSCs), muscle progenitor cells, and insulin-producing (islet) cells, with ongoing clinical development for regenerative medicine indications such as type 1 diabetes and various organ repair settings.

Other names

hypoimmunogenic cellsuniversal hypoimmune cellsHIP iPSCs